^
Association details:
| Biomarker: | EGFR L747P |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Rare Presentation of a Non-Asian Female With Metastatic Non-small-cell Lung Cancer Harboring EGFR L747P Mutation With Clinical Response to Multi-targeted Epigenetic and EGFR Inhibition
Published date:
01/01/2022
Excerpt:
We present the case of a patient diagnosed with stage IV lung adenocarcinoma….The patient was found to have an EGFR exon 19 (L747P) mutation, as evident in her liquid biopsy...this patient showed a substantial response when treated with erlotinib combined with epigenetic therapies, consisting of DNA methyltransferase and histone deacetylase inhibitors. For more than 8 years, the patient has been responding to combination therapy with a normal quality of life.
Secondary therapy:
DNA methyltransferase inhibitor + HDAC inhibitor
DOI:
10.21873/anticanres.15502
